CardioFocus Inc. raised $5.9 million of the $9.2 million it was after in a sale of its debt, according to a filing with the federal Securities and Exchange Commission.
The Marlborough device maker is developing a catheter-based system that uses lasers to treat atrial fibrillation. It’s currently in pre-marketing clinical trials under an investigational device exemption from the Food & Drug Administration.